Literature DB >> 18160816

SLC40A1 c.1402G-->a results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype.

Pauline L Lee1, Terri Gelbart, Carol West, James C Barton.   

Abstract

BACKGROUND/AIMS: To determine the molecular basis of a mild hemochromatosis phenotype in a man of Scottish-Irish descent.
METHODS: We sequenced genomic DNA to detect mutations of HFE, SLC40A1, TFR2, HAMP, and HFE2. RNA isolated from blood mononuclear cells was used to make cDNA. RT-PCR was performed to amplify ferroportin from cDNA, and amplified products were visualized by electrophoresis and sequenced.
RESULTS: The proband was heterozygous for the novel mutation c.1402G-->A (predicted G468S) in exon 7 of the ferroportin gene (SLC40A1). Located in the last nucleotide before the splice junction, this mutation results in aberrant splicing to a cryptic upstream splice site located at nt 990 within the same exon. This causes truncation of ferroportin after glycine 330 and the addition of 4 irrelevant amino acids before terminating. The truncated ferroportin protein, missing its C-terminal 241 amino acids, would lack all structural motifs beyond transmembrane region 7. The patient was also heterozygous for the common HFE H63D polymorphism, but did not have coding region mutations in TFR2, HAMP, or HFE2.
CONCLUSIONS: We conclude that this patient represents a unique example of hemochromatosis due to a single base-pair mutation of SLC40A1 that results in aberrant splicing and truncation of ferroportin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160816     DOI: 10.1159/000112830

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  8 in total

1.  Assessment of iron overload in a cohort of Sri Lankan patients with transfusion dependent beta thalassaemia and its correlation with pathogenic variants in HBB, HFE, SLC40A1, and TFR2 genes.

Authors:  Ruwangi Dissanayake; Nayana Samarasinghe; Samantha Waidyanatha; Sajeewani Pathirana; Nilaksha Neththikumara; Vajira H W Dissanayake; Kalum Wetthasinghe; Lallindra Gooneratne; Pujitha Wickramasinghe
Journal:  BMC Pediatr       Date:  2022-06-15       Impact factor: 2.567

2.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

Review 3.  Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene: A case report and a review of the literature.

Authors:  Wei Zhang; Tingxia Lv; Jian Huang; Xiaojuan Ou
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

4.  A case report of hereditary hemochromatosis caused by mutation of SLC40A1 gene.

Authors:  Xin Yin; Yu Zhang; Hui Gao; Qing-Long Jin; Xiao-Yu Wen
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Iron chelators reverse organ damage in type 4B hereditary hemochromatosis: Case reports.

Authors:  Ling-Yan Wu; Zhen-Ya Song; Qing-Hai Li; Li-Jun Mou; Ying-Ying Yu; Si-Si Shen; Xiao-Xiao Song
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

6.  The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

Authors:  Daniel F Wallace; V Nathan Subramaniam
Journal:  Genet Med       Date:  2015-12-03       Impact factor: 8.822

Review 7.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

Review 8.  Twenty Years of Ferroportin Disease: A Review or An Update of Published Clinical, Biochemical, Molecular, and Functional Features.

Authors:  L Tom Vlasveld; Roel Janssen; Edouard Bardou-Jacquet; Hanka Venselaar; Houda Hamdi-Roze; Hal Drakesmith; Dorine W Swinkels
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.